Paraza Pharma Inc. is pleased to announce a recent publication

A paper disclosing the discovery of TRPA1 receptor antagonist GDC-6599, a potential first-in-class therapy for respiratory diseases has just been published in the Journal of Medicinal Chemistry. This work was conducted in collaboration with Genentech.

Jack A. Terrett, Justin Q. Ly, Paula Katavolos, Catrin Hasselgren, Steven Laing, Fiona Zhong, Elisia Villemure, Martin Déry, Robin Larouche-Gauthier, Huifen Chen, Daniel G. Shore, Wyne P. Lee, Eric Suto, Kevin Johnson, Marjory Brooks, Alyssa Stablein, Francis Beaumier, Léa Constantineau-Forget, Chantal Grand-Maître, Luce Lépissier, Stéphane Ciblat, Claudio Sturino, Yong Chen, Baihua Hu, Justin Elstrott, Vineela Gandham, Victory Joseph, Helen Booler, Gary Cain, Carolina Chou, Aaron Fullerton, Michelle Lepherd, Shannon Stainton, Elizabeth Torres, Konnie Urban, Lanlan Yu, Yu Zhong, Linda Bao, Kang-Jye Chou, Jessica Lin, Wei Zhang, Hank La, Liling Liu, Teresa Mulder, Jun Chen, Tania Chernov-Rogan, Adam R. Johnson, David H. Hackos, Rebecca Leahey, Shannon D. Shields, Alessia Balestrini, Lorena Riol-Blanco, Brian S. Safina, Matthew Volgraf, Steven Magnuson, and Satoko Kakiuchi-Kiyota. Discovery of TRPA1 Antagonist GDC-6599: Derisking Preclinical Toxicity and Aldehyde Oxidase Metabolism with a Potential First-in-Class Therapy for Respiratory Disease  J. Med. Chem. 2024ASAP